+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cytochrome P450"

From
Cytochrome P450 17 (CYP17) Inhibitor - Pipeline Insight, 2022 - Product Thumbnail Image

Cytochrome P450 17 (CYP17) Inhibitor - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 60 Pages
  • Global
From
Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019 - Product Thumbnail Image

Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 42 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

The Cytochrome P450 market is a subset of the Endocrine and Metabolic Disorders Drugs market. Cytochrome P450 enzymes are involved in the metabolism of many drugs, hormones, and other substances. These enzymes are responsible for the breakdown of many drugs, including those used to treat endocrine and metabolic disorders. As such, the Cytochrome P450 market is an important part of the Endocrine and Metabolic Disorders Drugs market. The Cytochrome P450 market is composed of pharmaceutical companies that develop drugs that target these enzymes. These companies develop drugs that are designed to interact with the enzymes in order to increase or decrease their activity. This can be used to treat endocrine and metabolic disorders, as well as other conditions. Some companies in the Cytochrome P450 market include Pfizer, Merck, Novartis, and GlaxoSmithKline. These companies are involved in the development of drugs that target these enzymes, as well as other drugs used to treat endocrine and metabolic disorders. Show Less Read more